Jefferies Maintains Their Buy Rating on IQVIA Holdings (IQV)

Jefferies analyst David Windley maintained a Buy rating on IQVIA Holdings (IQVResearch Report) on July 11 and set a price target of $255.00. The company’s shares closed last Thursday at $209.11, close to its 52-week low of $194.67.

According to, Windley is a top 100 analyst with an average return of 15.3% and a 68.9% success rate. Windley covers the Healthcare sector, focusing on stocks such as West Pharmaceutical Services, Molina Healthcare, and Elevance Health.

Currently, the analyst consensus on IQVIA Holdings is a Strong Buy with an average price target of $259.36, representing a 24.1% upside. In a report issued on July 7, Robert W. Baird also maintained a Buy rating on the stock with a $260.00 price target.

See the top stocks recommended by analysts >>

IQVIA Holdings’ market cap is currently $40.09B and has a P/E ratio of 38.19.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

North Carolina-based IQVIA Holdings, Inc. provides advanced analytics, technology solutions, and contract research services to the life sciences industry. The company operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.

Read More on IQV:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More